Objective Our primary objective was to estimate an updated prevalence of SLE in France in 2020. We also explore the sociodemographic characteristics of patients with SLE, the social and spatial ...

The unpredictable nature of the SLE disease activity makes its management particularly challenging. Current treatment options for SLE focus on managing the inflammatory status, decreasing the symptoms ...

Background The interaction between fine particulate matter (PM2.5) and genetic factors can lead to epigenetic modifications, potentially increasing the risk of SLE development. However, the impact of ...

Objectives To assess brain grey matter alterations in patients with SLE and their correlation with neuropsychological testing using synthetic MRI (SyMRI).Methods This prospective study enrolled ...

Background and Aims Systemic Lupus Erythematosus (SLE) and its treatment predispose to infections such as human papillomavirus (HPV) that is a risk factor for the development of lower genital tract ...

Objective Systemic lupus erythematosus (SLE) disproportionately affects women and often develops during their reproductive years. Research suggests that some women who receive cyclophosphamide as ...

Objective This study aims to evaluate the diagnostic performance of the digital liquid chip method (DLCM) compared with indirect immunofluorescence (IIF) and chemiluminescent immunoassay (CLIA) for ...

Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...

O37 Male gender, educational level, disease activity, prednisone daily dose and previous medical adherence are predictive of medical adherence in systemic lupus erythematosus patients – Data from the ...

Background Mycophenolic acid (MPA) is recommended for the treatment of lupus nephritis (LN). However, the high pharmacokinetic (PK) variability of MPA contributes to its suboptimal efficacy and an ...

Objective To report the prevalence of disease activity in individual SLE organ domains, including prevalence stratified by the most common disease activity cut-off score for clinical trial eligibility ...

Objective Patients with SLE have a well-known increased risk of major comorbidities, although they are also very heterogeneous in terms of the prevalence of comorbid conditions. The relationships of ...